Vedanta Biosciences, Inc. Vedanta Biosciences, Inc.

  • Home
  • About
    • Overview
    • Team
    • Scientific Co-Founders and Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • VE303
    • VE202
    • VE800
    • VE707
    • VE416
    • Partnerships
    • Intellectual Property
  • Clinical Trials
    • VE303
    • VE800
    • VE416
    • VE202
    • Expanded Access
  • Platform
    • How Our Drugs Work
    • Discovery Platform
    • Manufacturing Platform
    • Publications
  • News & Media
    • Overview
    • Press Releases
    • In The News
  • Careers
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • In The News

Press Releases

Aug 16, 2016

Vedanta Biosciences Granted U.S. Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia

Aug 11, 2016

Vedanta Biosciences Announces Collaboration with the NYU Langone Medical Center to Develop Microbiome-Derived Immunotherapies for Cancer

Jun 6, 2016

Vedanta Biosciences Closes $50 Million Financing to Advance Microbiome Therapeutics

Mar 30, 2016

Vedanta Biosciences Announces License Agreement with RIKEN and other Japanese Institutions for New Immune Boosting Microbiome Technology

Mar 16, 2016

Vedanta Biosciences Appoints New Chief Scientific Officer and Expands to New Facility

Jan 11, 2016

Defense Secretary Carter Visits Vedanta

Oct 13, 2015

Vedanta Biosciences Expands Team with Additions of Head of Preclinical Development and Head of Intellectual Property

Jul 10, 2013

Pioneering Study Describes Rationally Designed Drug Candidate Derived From the Human Microbiota

Jun 27, 2013

Vedanta Enters Collaboration with Johnson & Johnson Innovation Center in Boston

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
RSS Feed
© 2023 Vedanta Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap